Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
NA
159 participants
INTERVENTIONAL
2021-12-29
2025-10-20
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Keywords
Explore important study keywords that can help with search, categorization, and topic discovery.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
RANDOMIZED
PARALLEL
TREATMENT
TRIPLE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Innovative myopia control spectacle lens
innovative myopia control spectacle lens
using a innovative spectacle lens to control myopia progression
Single vision spectacle lens
Single vision spectacle lens
single vision spectacle lens for myopia and astigmatism correction
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
innovative myopia control spectacle lens
using a innovative spectacle lens to control myopia progression
Single vision spectacle lens
single vision spectacle lens for myopia and astigmatism correction
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Spherical equivalent refractive error (SER) by manifest refraction between -0.75 and -4.50 D in each eye.
* Astigmatism, if present, of not more than 1.50 D.
* Difference in SER between the two eyes (Anisometropia) by manifest refraction not more than 1.00 D.
* Best corrected visual acuity in each eye equal to or better than +0.10 logMAR (≥ 20/25 as Snellen)
* Agree to wear spectacles for ≥10 hours/day at least 6 days/week.
* Willingness and ability to participate in trial for 3 years and attend scheduled visits.
Exclusion Criteria
* Strabismus by cover test at near or distance wearing correction.
* Amblyopia
* Any ocular or systemic condition known to affect refractive status (e.g., keratoconus, diabetes, Down's syndrome, etc.).
* Current use of ocular or systemic medications which, in the investigator's opinion, may significantly affect pupil size, accommodation or refractive state.
* Current or anticipated use of growth hormones.
* Participation in any clinical study within 30 days of the Baseline visit.
6 Years
12 Years
ALL
Yes
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Essilor International
INDUSTRY
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Scripps Poway Optometry
San Diego, California, United States
Sabal Eye Care
Longwood, Florida, United States
Illinois College of Optometry
Chicago, Illinois, United States
Kannarr Eye Care
Pittsburg, Kansas, United States
New England College of Optometry
Boston, Massachusetts, United States
SUNY College of Optometry
New York, New York, United States
Sacco Eye Group
Vestal, New York, United States
UPMC Children's Hospital of Pittsburgh
Pittsburgh, Pennsylvania, United States
Mann Eye Institute
Houston, Texas, United States
Countries
Review the countries where the study has at least one active or historical site.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
WS10246
Identifier Type: -
Identifier Source: org_study_id